💊

Sunitinib Accord

sunitinib

Gastrointestinal Stromal Tumors;Carcinoma, Renal Cell;Neuroendocrine Tumors

✅ Authorised Generic

✅

No active alerts

This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Gastrointestinal stromal tumour (GIST) Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance. Metastatic renal cell carcinoma (MRCC) Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults. Pancreatic neuroendocrine tumours (pNET) Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.

⚠️ Patient safety

Official EMA page

https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord